Han W. Tun - Concepedia

Author

Han W. Tun

Mayo Clinic in Florida ORCID

Also Known As

H Tun, H W Tun, H. Tun, H. W Tun, H. W. Tun, H.W. Tun, Han Tun, Han W Tun, Han W Tun, MD, Han W. Tun

330

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Florida WinnMed Jacksonville College Mayo Clinic Mayo Clinic in Arizona

About

Han W. Tun is an author at Mayo Clinic in Florida specializing in medicine, pathology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	23	875
2	Health Sciences	4	4	90
3	Natural Sciences	3	3	183
4	Nursing	1	1	50
5	Public Health	1	1	22

Han W. Tun

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma Christina A. Von Roemeling, Laura A. Marlow, Johnny J. Wei, Clinical Cancer Research	2013	273
Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes Yaqing Qie, Hengfeng Yuan, Christina A. Von Roemeling, Scientific Reports	2016	247
Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4 Christina A. Von Roemeling, Derek C. Radisky, Laura A. Marlow, Cancer Research Renal InflammationPathologyAmpa-selective Glutamate Receptor-4Cancer BiologyTumor Biology	2014	221
Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma Han W. Tun, Laura A. Marlow, Christina A. Von Roemeling, PLoS ONE	2010	182
Aberrant Lipid Metabolism in Anaplastic Thyroid Carcinoma Reveals Stearoyl CoA Desaturase 1 as a Novel Therapeutic Target Christina A. Von Roemeling, Laura A. Marlow, Anthony B. Pinkerton, The Journal of Clinical Endocrinology & Metabolism	2015	177
Pathway analysis of primary central nervous system lymphoma Han W. Tun, David Personett, Karen A. Baskerville, Blood	2008	165
A Novel γ-Secretase Assay Based on Detection of the Putative C-terminal Fragment-γ of Amyloid β Protein Precursor Inga Pinnix, Usha Musunuru, Han W. Tun, Journal of Biological Chemistry	2001	139
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma Han W. Tun, Patrick B. Johnston, Lisa M. DeAngelis, Blood	2018	127
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma Thomas E. Witzig, Craig B. Reeder, Jing Han, Blood	2015	109
Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models Zhimin Li, Yushi Qiu, David Personett, PLoS ONE Cns LymphomaLymphoid NeoplasiaCancer ImmunosurveillanceOncologyMedicine	2013	94

Page 1